CClinicalTrials.gg
Not yet recruitingNCT07576348Updated May 8, 2026

Electroacupuncture for Insomnia in Patients With Chronic Sciatica Due to Lumbar Disc Herniation: a Randomized Controlled Trial

An interventional study of Electroacupuncture and Sham electroacupuncture in Sciatica, Lumbar Disc Herniation and Insomnia, sponsored by Shanghai Yueyang Integrated Medicine Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Shanghai Yueyang Integrated Medicine Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if electroacupuncture can improve sleep in people with chronic sciatica caused by lumbar disc herniation. It will also assess the safety of this treatment. The main questions it aims to answer are whether electroacupuncture improves sleep quality and whether it reduces pain and improves daily function. Researchers will compare electroacupuncture to a sham treatment, which looks like real acupuncture but has little or no therapeutic effect, to determine its effectiveness. Participants will be randomly assigned to receive electroacupuncture or sham treatment, will receive treatment three times per week for four weeks, and will complete questionnaires about their sleep, pain, and daily activities.

02

Conditions studied

03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Participants will be eligible if they meet all of the following criteria:

  1. Aged 18-75 years, of either sex;
  2. Diagnosis with lumbar disc herniation accompanied by unilateral chronic sciatica (disease duration ≥ 3 months);
  3. Experiencing moderate to severe radiating leg pain (below the knee), defined as a Numerical Rating Scale (NRS) score ≥ 4 at screening within the past 24 h;
  4. Diagnosis of chronic insomnia, with a Pittsburgh Sleep Quality Index (PSQI) total score > 7;
  5. Onset or exacerbation of insomnia temporally associated with the onset or worsening of sciatica symptoms;
  6. Willing to participate and able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

Participants will be excluded if any of the following criteria are met:

  1. Spinal or structural conditions: lumbar spinal stenosis, spondylolisthesis, vertebral fracture, spinal infection (e.g., tuberculosis), or tumor;
  2. Surgical indications: cauda equina syndrome, conus medullaris syndrome, or other conditions requiring urgent surgical intervention;
  3. Severe systemic diseases: unstable cardiovascular, hepatic, renal, respiratory, or hematological disorders, or metabolic conditions that may significantly affect study outcomes (e.g., uncontrolled diabetes or thyroid disease);
  4. Neurological or psychiatric disorders: major neurological diseases (e.g., epilepsy, Parkinson's disease, dementia, multiple sclerosis) or severe psychiatric disorders (e.g., schizophrenia);
  5. Clinically significant depression or anxiety, defined as Patient Health Questionnaire-9 (PHQ-9) ≥ 10 and/or Generalized Anxiety Disorder-7 (GAD-7) ≥ 10;
  6. Other primary sleep disorders, including obstructive sleep apnea, narcolepsy, or restless legs syndrome;
  7. Use of centrally acting medications: regular use (≥ 3 days/week within 4 weeks prior to enrolment) of medications affecting the central nervous system (e.g., opioids, sedative-hypnotics, antidepressants) without an adequate washout period (≥ 2 weeks or longer depending on drug half-life);
  8. Irregular sleep patterns, including night shift work (≥ 2 times/week between 22:00-06:00) or highly irregular sleep-wake cycles;
  9. Pregnancy or lactation;
  10. History of substance abuse or dependence;
  11. Lumbar spine surgery or interventional procedures within the past 3 months;
  12. History of acupuncture treatment;
  13. Implanted electronic devices (e.g., pacemakers) or metal implants at acupuncture sites;
  14. Participation in another clinical trial within the past 3 months;
  15. Severe sensory or cognitive impairment affecting assessment compliance;
  16. Any other condition deemed by investigators to compromise safety or data integrity.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Electroacupuncture

    Procedure: Electroacupuncture

  • Sham comparator
    Sham electroacupuncture

    Procedure: Sham electroacupuncture

Interventions

  • ProcedureElectroacupuncture

    Electroacupuncture will be administered by a licensed acupuncturist. Adhesive foam pads will be applied at each acupoint to enhance blinding. Sterile needles will be inserted through the pads into the skin at predefined acupoints, including Sishencong (EX-HN1), bilateral Shenmen (HT7) and Sanyinjiao (SP6), Jiaji (EX-B2) at the L3-L5 levels (bilateral points at each segment), Shenshu (BL23), Dachangshu (BL25), and selected lower limb acupoints. Electrical stimulation will be applied using a sparse-dense wave (2/10 Hz) for 30 minutes per session. Treatment will be delivered three times per week for four weeks.

  • ProcedureSham electroacupuncture

    Sham electroacupuncture will be administered by a licensed acupuncturist. Adhesive foam pads will be applied at each non-acupoint to maintain blinding. Sterile needles will be inserted superficially (2-3 mm) through the pads without manipulation or eliciting deqi sensation. Electrical stimulation will be minimally applied only briefly at the beginning and end of each session to mimic the procedure. Treatment duration and frequency will be identical to the electroacupuncture group (30 minutes per session, three times per week for four weeks).

05

What researchers measure

Primary outcomes

  1. Pittsburgh Sleep Quality Index (PSQI) total score

    The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported instrument designed to assess sleep quality over the preceding month, with total scores ranging from 0 to 21, where higher scores denote poorer sleep quality.

    Time frame: Week 4

Secondary outcomes

  1. Numerical Rating Scale (NRS) score for leg pain intensity

    The 11-point Numerical Rating Scale (NRS) is a self-reported instrument used to assess average radiating leg pain intensity over the preceding 24 hours, with scores ranging from 0 to 10, where higher scores denote more severe pain.

    Time frame: Baseline, Week 2, Week 4, and Week 8

  2. Numerical Rating Scale (NRS) score for low back pain intensity

    The 11-point Numerical Rating Scale (NRS) is a self-reported instrument used to assess average low back pain intensity over the preceding 24 hours, with scores ranging from 0 to 10, where higher scores denote more severe pain.

    Time frame: Baseline, Week 4, and Week 8

  3. Oswestry Disability Index (ODI) score

    The Oswestry Disability Index (ODI) is a self-reported questionnaire used to assess disability related to lumbar spine disorders, with percentage scores ranging from 0% to 100%, where higher scores denote greater disability.

    Time frame: Baseline, Week 4, and Week 8

  4. Insomnia Severity Index (ISI) score

    The Insomnia Severity Index (ISI) is a self-reported instrument used to assess the subjective severity of insomnia, its impact on daytime functioning, and associated distress over the preceding two weeks, with total scores ranging from 0 to 28, where higher scores denote more severe insomnia.

    Time frame: Baseline, Week 2, Week 4, and Week 8

  5. Pittsburgh Sleep Quality Index (PSQI) total score

    The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported instrument designed to assess sleep quality over the preceding month, with total scores ranging from 0 to 21, where higher scores denote poorer sleep quality.

    Time frame: Week 8

  6. Proportion of participants achieving ≥50% reduction in Pittsburgh Sleep Quality Index (PSQI) total score

    The Pittsburgh Sleep Quality Index (PSQI) is a validated self-reported instrument designed to assess sleep quality over the preceding month, with total scores ranging from 0 to 21, where higher scores denote poorer sleep quality.

    Time frame: Week 4, Week 8

  7. Sleep efficiency measured by actigraphy

    Time frame: Baseline, Week 4

  8. Total sleep time measured by actigraphy

    Time frame: Baseline, Week 4

  9. Incidence of adverse events

    Time frame: From baseline to Week 8

Other outcomes

  1. Resting-state electroencephalography-derived microstate parameters

    Resting-state electroencephalography-derived microstate parameters, including mean duration, occurrence rate, time coverage, and transition probability, will be assessed at baseline and week 4. Mean duration refers to the average time for which a microstate class remains stable; occurrence rate refers to the number of occurrences per second; time coverage refers to the percentage of total recording time occupied by a microstate class; and transition probability refers to the probability of transition from one microstate class to another.

    Time frame: Baseline, Week 4

  2. Untargeted plasma metabolomic features

    Fasting plasma samples will be collected at baseline and week 4 and analyzed using an untargeted metabolomics approach based on ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS). Detected metabolomic features will be characterized by mass-to-charge ratio, retention time, relative ion intensity, and tandem mass spectrometry spectra.

    Time frame: Baseline, Week 4

  3. Credibility/Expectancy Questionnaire scores

    Treatment credibility and expectancy will be assessed before treatment using the Credibility/Expectancy Questionnaire. The credibility subscale consists of three items rated on a 1-9 scale, with a total score ranging from 3 to 27; higher scores indicate greater perceived treatment credibility. The expectancy subscale consists of three items assessing expected improvement and perceived treatment benefit. Two items are rated from 0% to 100%, and one item rated on a 1-9 scale will be transformed to a 0-100 scale; the three items will be averaged to generate a score ranging from 0 to 100, with higher scores indicating greater treatment expectancy.

    Time frame: Baseline

  4. Bang blinding index

    At week 4, before unblinding, participants will complete a structured blinding assessment question asking them to guess their treatment allocation as real electroacupuncture, sham electroacupuncture, or "uncertain." Blinding success will be quantified using the Bang blinding index and its 95% confidence interval. The Bang blinding index ranges from -1 to 1, with values close to 0 indicating successful blinding. Values between -0.2 and 0.2 will be interpreted as indicating adequate blinding.

    Time frame: Week 4

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07576348
Lead sponsor
Shanghai Yueyang Integrated Medicine Hospital
Responsible party
Sponsor
First posted
May 8, 2026
Start date
May 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 8, 2026

Study contacts

Ke Wang
Contact
wangke8430@163.com
+86 21-65161782-3136

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion